中國生物製藥(01177.HK)附屬與益方生物簽署獨家許可與合作協議
中國生物製藥(01177.HK)公布,附屬正大天晴與益方生物簽署獨家許可與合作協議。據此,正大天晴獲益方生物授予D-1553在中國大陸地區開發、註冊、生產和商業化的獨家許可權。同時,基於未來潛在的數據分享合作,正大天晴將適時被授予一定比例的中國大陸以外地區權益。
D-1553是益方生物自主研發的一款KRAS G12C抑制劑,用於治療帶有KRAS G12C突變的非小細胞肺癌、結直腸癌等多種癌症。(ca/u)
~
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.